FDA Brief

Warning letters Food

FDA warning letter to

EarthLab, Inc., dba Wise Woman Herbals

High riskIssued Apr 27, 2023Posted May 16, 2023Division of Human and Animal Food Operations West VI

FDA warned EarthLab, doing business as Wise Woman Herbals, over unapproved drug claims and supplement CGMP violations.

What happened

FDA inspected the Creswell, Oregon facility from April 4 to April 14, 2022, and reviewed the company's website and Facebook page in September and November 2022. The inspection found current good manufacturing practice (CGMP) violations, including missing specifications and release of ingredients that exceeded microbial or lead limits, some used in distributed products. The website and social media claims said products could prevent or treat diseases such as stroke, prostate cancer, flu, and joint pain, so FDA called them unapproved new drugs and misbranded.

What FDA found

  1. Website and Facebook claims said products could reduce stroke risk, fight prostate cancer, treat flu, or relieve joint pain, making them unapproved new drugs.

    FD&C Act § 201(g)(1)(B), § 201(p), § 505(a) [21 U.S.C. § 321(g)(1)(B), § 321(p), § 355(a)]
  2. Four products were intended for diseases a layperson cannot safely self-treat, so they lacked adequate directions and were misbranded.

    FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5
  3. The company did not establish required written specifications for components or finished products, including identity, purity, strength, and composition.

    21 CFR 111.70(a), (b), (e)
  4. Quality control did not reject components that failed microbial or lead specifications, and some were used in finished products distributed to customers.

    21 CFR 111.113(b)(2)
  5. The company did not follow its own written microbiology retesting procedure for an out-of-specification Kava Capsules lot.

    21 CFR 111.303
  6. The company did not establish and follow QC-reviewed laboratory control processes, including reference standards, for near-infrared identity testing.

    21 CFR 111.315(d); 21 CFR 111.320(a)

What FDA wants

FDA asks the company to notify it in writing within 15 working days of receipt of the specific steps taken to address the violations, explain how it will prevent recurrence, and include copies of related documentation.

Who should pay attention

  • retailers and online sellers of Wise Woman Herbals products
  • dietary supplement brands that use herbal ingredients
  • quality teams managing specifications and out-of-specification investigations

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk